VERTEX-809 –Phase 2a trial evaluated the potential effect of an oral compound to improve trafficking of the defective CFTR protein (corrector) –To evaluate the effect of VX-809 on biomarkers of CFTR activity homozygotes for the F508del: –Spirometry (forced expiratory volume in 1 second [FEV1]) –Sweat chloride concentration –Nasal potential difference (NPD) –Cystic Fibrosis Questionnaire-Revised (CFQ-R)
{"Image DocumentName": "VERTEX-809Phase 2a trial evaluated the potential effect of an oral compound to improve trafficking of the defective CFTR protein (corrector)", "Image ImageDescription": "To evaluate the effect of VX-809 on biomarkers of CFTR activity homozygotes for the F508del: Spirometry (forced expiratory volume in 1 second [FEV1]) Sweat chloride concentration. Nasal potential difference (NPD) Cystic Fibrosis Questionnaire-Revised (CFQ-R)", "Image XResolution": "37", "Image YResolution": "37", "Image ResolutionUnit": "Pixels/Centimeter", "Image Software": "SlidePlayer", "Image YCbCrPositioning": "Centered"}